25Aug
Johnson & Johnson Announces Acquisition of Momenta For $6.5 Billion
Johnson and Johnson announced that it has entered into an agreement to acquire Momenta Pharmaceuticals, Inc. for $6.5 billion. The acquisition gives J&J’s Janssen unit full global rights to Momenta’s nipocalimab (M281), an anti-FcRn antibody designed to treat a number of autoantibody-driven disorders, including generalized myasthenia gravis (gMG), warm autoimmune hemolytic anemia (wAIHA), and hemolytic disease of the fetus and newborn (HDFN)....
By:
Goodwin
Related
Orrick’s Equal Pay Pulse has been tracking the nationwide wave of salary history bans in recent yea...
Read More >
A majority of dealmakers say their companies are focused on defense or survival, but about a quarter...
Read More >
On July 31, 2019, Governor Pritzker signed into law Public Act 101-0177, which, for the second time ...
Read More >
As the pace of SPAC IPOs continues to set records, evolution of the economic terms has accelerated. ...
Read More >
A federal district court in Washington recently held that a claims handling mishap resulted in a wai...
Read More >
In keeping with its commitment to offer more technical guidance for government contractors across al...
Read More >